Journal
CHEMNANOMAT
Volume 6, Issue 9, Pages 1373-1385Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/cnma.202000229
Keywords
Chitosan nanoparticles; Drug delivery; Melanoma cancer; Microfluidic; Paclitaxel
Ask authors/readers for more resources
In the present study, the effectiveness of paclitaxel nanocrystals (PTX NCs) encapsulated in carboxymethyl chitosan (CMCS) nanoparticles (CMCS-PTX NPs) as an anticancer drug is evaluated. The CMCS nanoparticles are produced via a cross-junction microfluidic device where the PTX/CMCS concentration and flow rates in the device are optimized. The dynamic light scattering data show that the PTX NCs have a median diameter size of 230 +/- 90 nm, while the size of CMCS-PTX NPs is roughly 270 +/- 30 nm. The zeta-potential result indicates less negative surface charge for the CMCS-PTX NPs as compared to the PTX NCs. Moreover, scanning electron microscopy micrographs, differential scanning calorimetry thermograms, and X-ray diffraction patterns reveal that the physicochemical properties of the drug remain unaltered after perfusion through the microfluidic device. Cytotoxicity and cell endocytosis of PTX NCs and CMCS-PTX NPs are evaluated in vitro using G361 melanoma-positive skin cells. The results reveal that the CMCS-PTX NPs increase the cellular uptake and cytotoxicity compared to the PTX NCs alone. In addition, the antitumor effect of CMCS-PTX NPs on B16 melanoma indicates the great potential of CMCS as a promising nano-carrier for PTX NCs drug with potent inhibitory effect on the tumor growth.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available